APT Medical

APT Medical ROE

The Return on Equity (ROE) of APT Medical (688617.SS) as of Oct 22, 2026 is 26.57 %. In the previous year, Return on Equity (ROE) was 26.75 % — a change of -0.68% (lower).

ROE

26.57 %

YoY

-0.68%

Last updated:

In 2025, APT Medical's return on equity (ROE) was 26.57 %, a -0.68% increase from the 26.75 % ROE in the previous year.

The APT Medical ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
7.97 CNY
Jan 1, 2019
23.62 CNY
Jan 1, 2020
24.06 CNY
Jan 1, 2021
11.69 CNY
Jan 1, 2022
20.30 CNY
Jan 1, 2023
28.00 CNY
Jan 1, 2024
26.75 CNY
Jan 1, 2025
26.57 CNY
The APT Medical ROE history
YEARROEYoY
26.57 %-0.68%
26.75 %-4.45%
28.00 %+37.89%
20.30 %+73.64%
11.69 %-51.41%
24.06 %+1.87%
23.62 %+196.29%
7.97 %-50.48%
16.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

APT Medical Stock analysis

What does APT Medical do? APT Medical Inc generates revenue through the research, development, production, and sale of electrophysiology, coronary access, and peripheral vascular intervention medical devices. The company offers electrophysiological electrode catheters, controllable radiofrequency ablation electrode catheters, and multichannel electrophysiological systems under its electrophysiology product line. Its coronary access segment includes guide wires, micro catheters, balloons, contrast guide wires, and catheters. Peripheral vascular intervention products address peripheral vascular diseases and are sold domestically and internationally. The firm also engages in original equipment manufacturer (OEM) business, producing products for other brands. Domestic and overseas markets are the primary sales channels for all product segments. The company's electrophysiology products target healthcare providers specializing in cardiac procedures, while coronary access devices serve interventional cardiologists and vascular surgeons. Peripheral vascular intervention solutions are marketed to hospitals and clinics treating vascular conditions. OEM partnerships allow APT Medical to supply components to other medical device manufacturers without direct branding. These segments collectively drive revenue through direct sales to healthcare institutions and international distributors. APT Medical Inc's product portfolio includes electrophysiological systems and coronary access tools that cater to specific medical specialties. The firm's peripheral vascular intervention products are designed for treating conditions like peripheral artery disease. OEM business contributes to revenue by manufacturing components for other companies' branded products. Domestic market sales and overseas distribution networks form the core of the company's commercial strategy, with no mention of specific customer names or financial figures beyond the employee count. APT Medical is one of the most popular companies on Eulerpool.

ROE Details

Decoding APT Medical's Return on Equity (ROE)

APT Medical's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing APT Medical's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

APT Medical's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in APT Medical’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about APT Medical stock

Return on Equity (ROE) of APT Medical is 26.57 % in 2025.

Return on Equity (ROE) of APT Medical changed from 26.75 % to 26.57 %, representing a -0.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) APT Medical since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s APT Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — APT Medical

All Key Metrics — APT Medical